Ausgabe 10/2018
Inhalt (20 Artikel)
Up front
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Chiara Ghezzi, Donald D. F. Loo, Ernest M. Wright
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas, David Z. I. Cherney
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma, John J. V. McMurray
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Beatrice C. Lupsa, Silvio E. Inzucchi
SGLT inhibitor adjunct therapy in type 1 diabetes
Rory J. McCrimmon, Robert R. Henry
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Christoph Wanner, Nikolaus Marx
Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events
Toshiaki Ohkuma, Sanne A. E. Peters, Mark Woodward
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Naveed Sattar, David Fitchett, Stefan Hantel, Jyothis T. George, Bernard Zinman
Gluten intake and risk of type 2 diabetes in three large prospective cohort studies of US men and women
Geng Zong, Benjamin Lebwohl, Frank B. Hu, Laura Sampson, Lauren W. Dougherty, Walter C. Willett, Andrew T. Chan, Qi Sun
Genome-wide association study of coronary artery disease among individuals with diabetes: the UK Biobank
Tove Fall, Stefan Gustafsson, Marju Orho-Melander, Erik Ingelsson
Identification of a missense variant in the WFS1 gene that causes a mild form of Wolfram syndrome and is associated with risk for type 2 diabetes in Ashkenazi Jewish individuals
Vikas Bansal, Bernhard O. Boehm, Ariel Darvasi
Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome
Manabu Kondo, Katsuya Tanabe, Kikuko Amo-Shiinoki, Masayuki Hatanaka, Tsukasa Morii, Harumi Takahashi, Susumu Seino, Yuichiro Yamada, Yukio Tanizawa
MANF protects human pancreatic beta cells against stress-induced cell death
Elina Hakonen, Vikash Chandra, Christopher L. Fogarty, Nancy Yiu-Lin Yu, Jarkko Ustinov, Shintaro Katayama, Emilia Galli, Tatiana Danilova, Päivi Lindholm, Aki Vartiainen, Elisabet Einarsdottir, Kaarel Krjutškov, Juha Kere, Mart Saarma, Maria Lindahl, Timo Otonkoski
Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice
Andrew T. Templin, Daniel T. Meier, Joshua R. Willard, Tami Wolden-Hanson, Kelly Conway, Yin-Guo Lin, Patrick J. Gillespie, Krister B. Bokvist, Giorgio Attardo, Steven E. Kahn, Donalyn Scheuner, Rebecca L. Hull
Programming of central and peripheral insulin resistance by low birthweight and postnatal catch-up growth in male mice
Lindsey M. Berends, Laura Dearden, Yi Chun L. Tung, Peter Voshol, Denise S. Fernandez-Twinn, Susan E. Ozanne
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
Md Abdul Hye Khan, Lauren Kolb, Melissa Skibba, Markus Hartmann, René Blöcher, Ewgenij Proschak, John D. Imig
More work is needed to better understand diabetes distress as a predictor of all-cause mortality in type 2 diabetes
Nanna Lindekilde, Frans Pouwer